Cost Effectiveness Assessment (2025-)

• Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
  November 12, 2026

• Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
  November 6, 2026

• Chuikyo Reps Back More Pharma Access to CEA Deliberations, Urge Neutrality
  October 29, 2026

• LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
  October 20, 2026

• CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
  October 16, 2026

• 3 Pharma Groups Press Government to Rethink CEA Expansion
  October 8, 2026

• Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
  October 5, 2026

• Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
  October 1, 2026

• CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
  September 30, 2026

• More Company Involvement in CEA a Big Positive: C2H Researcher
  September 29, 2026

• Pharma Groups Press for Freeze on CEA Price Cuts, Cite Unresolved Issues
  September 17, 2026

• CEA Review Has not Settled Debate, LDP Lawmaker Says
  September 15, 2026

• Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
  September 10, 2026

• CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
  September 8, 2026

• Kisunla Braced for NHI Price Cut after CEA; Leqembi Method to Apply
  August 27, 2026

• CEA Review Group Wraps Up Technical Debate, Urges More Company Access
  August 19, 2026

• Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
  August 6, 2026

• CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
  August 5, 2026

• CEA Review Group Debates Comparator Technologies, ICER Uncertainty
  July 14, 2026

• Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
  June 25, 2026

ページ